Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/241—Tumor Necrosis Factors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2202/00—Special media to be introduced, removed or treated
  • A61M2202/07—Proteins

Definitions

• the invention relates to the needle-free subcutaneous application of proteins to humans and animals by means of a device for delivering proteins comprising a unit of nozzle, chamber, piston, actuator and drive and a corresponding method and its use.
• proteins relate to such agents as growth factors, antibodies, hormones, enzymes, inhibitors / receptor antagonists, coagulation factors and cytokines.
• agents based on proteins are routinely used today:
• Antithrombotics asthma, respiratory infections, antigens, anemia (epoetin), blood disease, diabetes (insulin), fertility disorder, hepatitis B / C (peginterferon alfa-2a / 2b), fractures, cancer, macular degeneration (AMD), mucoviscidosis
• Mucosal inflammation (palifermin), psoriasis, sepsis (drotrecogin alfa), metabolic disorders, transplantation (basiliximab),
• a largely similar glycosylation pattern is obtained for those proteins produced by well-established cell lines, such as baby hamster kidney (BHK) cells, Chinese hamster ovary (CHO) cells, or human fibroblast cells.
• BHK baby hamster kidney
• CHO Chinese hamster ovary
• the needle-free subcutaneous administration is vertical to the skin surface and not tangential.
• the invention relates to a device for delivering proteins comprising a unit of nozzle, chamber, piston, actuator and actuator for use in the needle-free subcutaneous application (of a protein) to humans or animals.
• the device is designed as a disposable system, so that only a single use ("ready for use") is possible. Consequently, the protein to be administered is already provided in the chamber.
• the chamber may be filled with the protein for this purpose and routinely e.g. be prepared by means of a conventional snap device in the device (also: applicator).
• the protein to be administered may be present in the chamber in dissolved form as a protein solution or protein melt.
• the protein solution or protein melt may contain an aqueous buffer solution and other conventional additives and auxiliaries.
• Such a protein solution may also comprise a formulation consisting of protein, liquid medium, polysaccharides, such as required for therapeutic proteins, in particular vaccines.
• a cylindrical chamber with a terminal radial taper which opens into a nozzle allows optimized shear thinning as a function of the shear rate of the previously described protein solutions as a polymeric fluid. This allows a substantial retention of the efficacy of the relevant therapeutic proteins and a qualitatively gentle application of the proteins. Consequently, according to the invention, an optimized chamber for proteins for their needle-free subcutaneous administration could be achieved.
• Such a cylindrical chamber with a terminal radial taper, which opens into a nozzle is shown by way of example in Figures 3, 4a and 4b.
• the taper is funnel-shaped.
• the length of the taper or the funnel can be 4 to 7 mm, with a cylindrical chamber with a diameter of 4 to 7 mm (see Figure 4a).
• the invention relates to a device for delivering proteins comprising a unit of nozzle, chamber, piston, actuator and drive, also for use in needle-free subcutaneous application (of a protein) to humans or animals, the device having a cylindrical chamber with a terminal having radial taper, which opens into a nozzle.
• the chamber or the chamber walls of an inert material preferably a plastic, in particular a thermoplastic with good thermoplastic flow, high stiffness, strength and hardness, which generates low frictional forces for the protein, such as cyclo-olefin -Copolymers (COC), in particular Topas®.
• COC advantageously has a high biocompatibility with respect to proteins.
• the aforementioned measures according to the invention also advantageously prevent bursting of the chamber during application or application.
• the invention relates to a chamber containing a protein, in particular protein solution, wherein the chamber consists of a plastic, in particular thermoplastics, preferably cyclo-olefin copolymers (COC), particularly preferably Topas®.
• a plastic in particular thermoplastics, preferably cyclo-olefin copolymers (COC), particularly preferably Topas®.
• COC cyclo-olefin copolymers
• Topas® cyclo-olefin copolymers
• the device is provided by removing a cap immediately for needleless subcutaneous application.
• the inventors were able to show that needle-less subcutaneous administration leads to surprisingly high plasma values of the administered protein. It is essential to the invention that the applied protein in this case retains its effect-specific functionality, so that in a most suitable manner e.g. Drugs based on a protein can be applied. This allows a reproducible dosage and increases patient safety. In addition, an improved pharmacokinetics is ensured.
• the drive consists of a spring drive, e.g. DE 10 2008 063 519 A1, DE 10 2007 004 21 1 A1, DE 10 2007 018 868 A1 or DE 10 2007 032 464 A1 of the Applicant, or a gas drive, such as e.g. described in EP 1 125 593 B1 or EP 1 243 281 B1, or a pyrotechnic drive, such as e.g. in EP 1 292 344 B1.
• a spring drive e.g. DE 10 2008 063 519 A1, DE 10 2007 004 21 1 A1, DE 10 2007 018 868 A1 or DE 10 2007 032 464 A1 of the Applicant
• a gas drive such as e.g. described in EP 1 125 593 B1 or EP 1 243 281 B1
• a pyrotechnic drive such as e.g. in EP 1 292 344 B1.
• the front closed end of the chamber has at least one or more nozzles, or even multi-hole systems, as described, for example, in DE 20 2008 017 814 U1.
• a suitable nozzle can for example be realized by a cavity body with input and output.
• the diameter may be, for example, 0.1 mm to 1 mm.
• the chamber volume may preferably be from 0.1 ml to about 2.0 ml, taking into account different inner diameters of the chamber.
• the chamber is suitable for receiving a protein to be administered.
• a "protein” is understood as meaning a polypeptide which may be chemically modified, such as, for example, glycolization, alkylation, etc.
• the protein may be a drug or therapeutic agent Antibodies, particularly a monoclonal or polyclonal antibody, an antigen, or a protein having one or more epitopes
• the proteins may be biochemically functionally defined, such as, but not limited to, growth factors, antibodies, hormones, enzymes, inhibitors
• it may be preferable that the proteins have more than 50 amino acids, in particular more than 100 amino acids and / or more than 50 amino acids, and / or receptor antagonists, coagulation factors, vaccines and cytokines as well as a protein solution or protein melt (corresponding to a polymer melt). or a molecular mass size r than 1 kDa, in particular greater than 10 kDa.
• needle-free means that no piercing of a needle into the tissue (skin) is required, but the device according to the invention is suitable for injection, but without making use of a needle in the broadest sense Synonym can be referred to as “needleless” injection become.
• needle-free subcutaneous administration means that a protein is administered parenterally or transdermally, with the application affecting the tissue under the skin .
• This subcutaneous tissue tela subcutanea or subcutis
• the invention relates to a method for needle-free subcutaneous application of a protein to humans or animals, wherein a.) A device for delivering proteins comprising a unit of nozzle, chamber, piston, B.) Is optionally aligned vertically to the skin surface and c.) Is held on the skin surface for at least 10 seconds after triggering the actuator.
• the method can be configured further according to one of the preformed embodiment of a device according to the invention.
• the invention relates to the use of a device for delivering proteins comprising a unit of nozzle, chamber, piston, actuator and drive for needle-free subcutaneous application of a protein to humans or animals.
• the use can be configured further according to one of the preformed embodiment of a device according to the invention or a method according to the invention.
• the invention relates to agents containing proteins for use in the needle-free subcutaneous application of a protein to humans or animals comprising a device consisting of a unit of nozzle, chamber, piston, actuator and drive.
• the means may be further configured according to one of the preformed embodiment of a device according to the invention or a method according to the invention.
• Needle-free application system (also: applicator) is filled with 0.5 ml adalimumab (Humira 40 mg / 0.8 ml). Per application 25 mg adalimumab are administered subcutaneously. As an approved animal model pigs are used.
• Figure 1 shows an exemplary device according to the invention consisting of a unit with nozzle (1), chamber (2), piston (3), actuator (4), drive (5) with removable cap (6).
• Figure 2 shows a comparison of needle-free subcutaneous administration (triangles, "nfi") for non-needle-free subcutaneous administration (squares, "inj"), starting from the same amounts / dosage, the plasma concentration (ng / ml) of adalimumab from Example 1 versus time in days (d).
• nfi needle-free subcutaneous administration
• inj squares, "inj”
• FIG. 3 shows, in a longitudinal section in the cutout, a cylindrical chamber with a terminal radial taper (7), which opens into a nozzle.
• FIG. 4a shows, in a longitudinal section in the detail of FIG. 3, a cylindrical chamber with a terminal radial taper (7), which opens into a nozzle.
• Figure 4b shows a cross section of a cylindrical chamber with a terminal radial taper (7), which opens into a nozzle.

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=49118406

Family Applications (1)

Country Status (7)

Families Citing this family (1)

Family Cites Families (18)

• 2014
  • 2014-09-09 CN CN202010417589.0A patent/CN111569195A/zh active Pending
  • 2014-09-09 JP JP2016539589A patent/JP2016529052A/ja active Pending
  • 2014-09-09 CN CN201480049519.7A patent/CN105530974A/zh active Pending
  • 2014-09-09 US US14/916,831 patent/US20160220757A1/en not_active Abandoned
  • 2014-09-09 EP EP14781454.5A patent/EP3043846A1/de not_active Withdrawn
  • 2014-09-09 CA CA2923492A patent/CA2923492A1/en not_active Abandoned
  • 2014-09-09 WO PCT/EP2014/069229 patent/WO2015032997A1/de active Application Filing
• 2016
  • 2016-05-16 HK HK16105594.1A patent/HK1217454A1/zh unknown
• 2020
  • 2020-02-28 JP JP2020032557A patent/JP2020110606A/ja not_active Abandoned

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events